Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Dapagliflozin is a prescription sodium-glucose cotransporter 2 inhibitor. Current U.S. labeling includes type 2 diabetes treatment from age 10 and adult indications involving heart failure and chronic kidney disease. Tablets come in 5 mg and 10 mg strengths and are taken once daily with or without food.
read more about dapagliflozin ...SGLT2 in the proximal kidney tubules reabsorbs most filtered glucose. Dapagliflozin inhibits SGLT2, reducing glucose reabsorption and increasing urinary glucose excretion. This lowers blood glucose in type 2 diabetes. Its heart failure and kidney benefits extend beyond glucose lowering, though their full mechanisms are not defined in the label.
Dapagliflozin is used with diet and exercise for type 2 diabetes in adults and patients age 10 and older. In adults, it also reduces selected heart failure outcomes and reduces the risk of kidney decline, end-stage kidney disease, cardiovascular death, and heart failure hospitalization in chronic kidney disease at risk of progression.
For glycemic control in type 2 diabetes, treatment starts at 5 mg once daily and can increase to 10 mg once daily. Adult heart failure, chronic kidney disease, and cardiovascular risk-reduction indications use 10 mg once daily. Kidney function and volume status are assessed before treatment, and kidney thresholds differ by indication.
Serious risks include ketoacidosis, volume depletion, acute kidney injury, serious urinary infections, genital fungal infections, Fournier gangrene, and low blood glucose when used with insulin or insulin secretagogues. Treatment is withheld before major surgery or prolonged fasting when clinically appropriate. It is not recommended for glycemic control in type 1 diabetes.
Yes. Dapagliflozin blocks sodium-glucose cotransporter 2 in the kidney.
Dapagliflozin is taken once daily with or without food.
Yes. Current U.S. labeling includes type 2 diabetes treatment in patients age 10 and older.
Yes. In adults at risk of progression, it reduces selected kidney and cardiovascular outcomes under current labeling.
Dapagliflozin. MedlinePlus. https://medlineplus.gov/druginfo/meds/a614015.html. Date Accessed September 24, 2026.
Dapagliflozin. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/9887712. Date Accessed September 24, 2026.
DailyMed - DAPAGLIFLOZIN tablet. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08baca21-e39e-4e61-961f-d89432fe8007. Date Accessed September 24, 2026.
DailyMed - FARXIGA (dapagliflozin) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72ad22ae-efe6-4cd6-a302-98aaee423d69. Date Accessed September 24, 2026.
FDA Label - FARXIGA (dapagliflozin) Tablets. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/202293s035lbl.pdf. Date Accessed September 24, 2026.